Aprea Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Aprea Therapeutics

01/11/2021 12:31

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected to show
no change in quarterly revenue when it reports  results on
November 3 (estimated). 
​* Refinitiv's mean analyst estimate for Aprea Therapeutics Inc
is for a loss of 45 cents per share. For the same quarter last
year, the company reported a loss of 58 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell." 
* The mean earnings estimate of analysts had risen by about 2.1%
in the last three months. ​
* Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $4​, about 23.8% below​ its last closing
price of $4.95. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.46       -0.47      -0.48     Missed  -2.7
 Mar. 31 2021  -0.48       -0.49      -0.46     Beat    6.6
 Dec. 31 2020  -0.67       -0.64      -0.73     Missed  -13.6​
 Sep. 30 2020  -0.76       -0.76      -0.58     Beat    23.7
 Jun.          -0.60​      -0.60      -0.78     Missed  -29.5​
 30​ 2020​                                              
 Mar. 31 2020  -0.57       -0.57      -0.45     Beat    20.7​
 Dec. 31 2019              -0.40      -0.64     Missed  -60
 Sep. 30 2019  -3.95       -3.94      -5.29     Missed  -34.2
 This summary was machine generated November 1 at 12:31 GMT.  All
figures in US dollars unless otherwise stated